Berenberg Bank set a €85.00 ($101.19) price target on Morphosys (ETR:MOR) in a report published on Thursday. The brokerage currently has a buy rating on the stock.
A number of other analysts have also recently weighed in on MOR. Commerzbank set a €76.00 ($90.48) price target on Morphosys and gave the company a buy rating in a research note on Thursday, August 31st. J P Morgan Chase & Co restated a neutral rating on shares of Morphosys in a research note on Wednesday, September 6th. Goldman Sachs Group set a €55.00 ($65.48) price target on Morphosys and gave the company a neutral rating in a research note on Thursday, September 7th. Deutsche Bank set a €90.00 ($107.14) price target on Morphosys and gave the company a buy rating in a research note on Thursday, September 7th. Finally, Independent Research set a €77.00 ($91.67) target price on Morphosys and gave the stock a buy rating in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of €82.25 ($97.92).
Morphosys (ETR:MOR) traded up €2.12 ($2.52) during midday trading on Thursday, reaching €80.52 ($95.86). The company had a trading volume of 107,325 shares, compared to its average volume of 169,282. Morphosys has a 12 month low of €42.56 ($50.67) and a 12 month high of €83.83 ($99.80).
COPYRIGHT VIOLATION WARNING: “Morphosys (MOR) Given a €85.00 Price Target by Berenberg Bank Analysts” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/08/morphosys-mor-given-a-85-00-price-target-by-berenberg-bank-analysts.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for Morphosys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys AG and related companies with MarketBeat.com's FREE daily email newsletter.